Rationale for the ASSAIL-MI-trial: a randomised controlled trial designed to assess the effect of tocilizumab on myocardial salvage in patients with acute ST-elevation myocardial infarction (STEMI)

INTRODUCTION: Interleukin-6 (IL-6) may be involved in ischaemia-reperfusion injury and myocardial remodelling after myocardial infarction (MI). We have recently shown that IL-6 inhibition by tocilizumab attenuates systemic inflammation and troponin T-release in patients with acute non-ST elevation M...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Open Heart
Autors principals: Anstensrud, Anne Kristine, Woxholt, Sindre, Sharma, Kapil, Broch, Kaspar, Bendz, Bjørn, Aakhus, Svend, Ueland, Thor, Amundsen, Brage H, Damås, Jan Kristian, Hopp, Einar, Kleveland, Ola, Stensæth, Knut Haakon, Opdahl, Anders, Kløw, Nils-Einar, Seljeflot, Ingebjørg, Andersen, Geir Øystein, Wiseth, Rune, Aukrust, Pål, Gullestad, Lars
Format: Artigo
Idioma:Inglês
Publicat: BMJ Publishing Group 2019
Matèries:
Protocol
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6803013/
https://ncbi.nlm.nih.gov/pubmed/31673391
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/openhrt-2019-001108
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars